Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment.
Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the Metastatic Breast Cancer Program, Dana-Farber Cancer Institute, highlights the need for further investigation into trastuzumab deruxtecan (Enhertu; T-DXd) in breast cancer treatment.
In this interview, she explains some areas for future research of T-DXd based on findings from an analysis of the DESTINY-Breast03 trial (NCT03529110). While she explains that there is a small amount of data in the HER2-low brain metastasis space at the moment, experts are awaiting more data to see how T-DXd performs in HER2-low brain metastasis.
Transcription:
0:09 | T-DXd is also FDA-approved in patients with metastatic breast cancer that have low expression of HER2, and so now we are investigating whether or not T-DXd works for patients with low levels of HER2 and brain metastasis.
0:31 | We have a small amount of data in HER2-low brain metastasis so far. The patients with brain metastasis were analyzed retrospectively from the DESTINY-Breast04 clinical trial [NCT03734029], and it is looking like there is an intracranial response rate around 25% in those patients, which actually for HER2-low or historically, HER2-negative brain metastasis is respectable. It is promising and I think that we are awaiting more data on how T-DXd performs in HER2-low brain metastasis, but I think that is a promising area.
1:16 | I would also say that HER2 is expressed in other types of solid tumors, [including in] some [gastrointestinal] tumors, some endometrial cancer, and we just got an approval for T-DXd in all solid tumors that are HER2-overexpressed with an [immunohistochemistry] score of 3+. Those tumors also have a higher propensity that is high HER2-expressing to go to the brain. This could be an option for patients that are HER2-expressing with brain metastasis in other solid tumors, which is exciting.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen